Standout Papers

ESMO recommendations on microsatellite instability testing for ... 2015 2026 2018 2022 647
  1. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach (2019)
    Claudio Luchini, Frédéric Bibeau et al. Annals of Oncology
  2. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015)
    Nicoletta Colombo, Carien L. Creutzberg et al. International Journal of Gynecological Cancer
  3. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts (2016)
    Ellen Stelloo, Remi A. Nout et al. Clinical Cancer Research
  4. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative (2015)
    Ellen Stelloo, Tjalling Bosse et al. Modern Pathology
  5. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022)
    Ana Oaknin, Tjalling Bosse et al. Annals of Oncology
  6. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trials (2015)
    Tjalling Bosse, Elke E.M. Peters et al. European Journal of Cancer
  7. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups (2018)
    Tjalling Bosse, Remi A. Nout et al. The American Journal of Surgical Pathology
  8. Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas (2019)
    Alicia León‐Castillo, Remi A. Nout et al. The Journal of Pathology

Immediate Impact

6 by Nobel laureates 19 from Science/Nature 62 standout
Sub-graph 1 of 22

Citing Papers

A vision–language foundation model for precision oncology
2025 StandoutNature
Understanding the complexity of p53 in a new era of tumor suppression
2024 Standout
2 intermediate papers

Works of Tjalling Bosse being referenced

p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies
2019
The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses
2018
and 1 more

Author Peers

Author Last Decade Papers Cites
Tjalling Bosse 4965 3581 2275 153 9.3k
Russell Vang 2055 4053 1818 167 7.7k
Brooke E. Howitt 1779 1947 2045 150 6.4k
Paul DiSilvestro 2503 3786 1885 153 6.2k
Claes G. Tropé 2050 4269 2343 212 8.4k
Helga B. Salvesen 2524 1755 1576 153 6.7k
Mansoor Raza Mirza 2245 3407 2461 203 6.1k
Philipp Harter 3296 7842 5155 313 11.8k
Larry J. Copeland 2631 4399 1990 207 7.5k
Walter H. Gotlieb 2201 2402 1533 230 6.2k
Blaise Clarke 1296 1805 1481 156 5.0k

All Works

Loading papers...

Rankless by CCL
2026